Phase III trial shows vosaroxin improves overall survival in acute myeloid leukaemia
Persistence of preleukemic clones in acute myeloid leukemia (AML) complete remission
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Progress in the development of treatments for leukemia
CAR T-cells and fast cars